TITUSVILLE, N.J., Oct. 8 /PRNewswire/ -- Preliminary results from a clinical study comparing INVEGA(TM) (paliperidone) Extended-Release Tablets to quetiapine (marketed as Seroquel(R)) and placebo in patients with recent, acute exacerbation of schizophrenia will be the subject of a poster on display during the 20th Annual U.S. Psychiatric and Mental Health Congress, which takes place October 11-14, 2007 in Kissimmee, FL.
The poster, entitled "A Comparative Analysis of Paliperidone ER and Quetiapine in Patients With a Recent, Acute Exacerbation of Schizophrenia" will be on display on Saturday, Oct. 13 from 2:15 p.m. to 5:15 p.m. at the Gaylord Palms Resort & Convention Center.
INVEGA is an atypical antipsychotic medication approved for acute and maintenance treatment of patients with schizophrenia. Janssen, L.P, markets INVEGA in the U.S.
IMPORTANT SAFETY INFORMATION FOR INVEGA(TM)
INVEGA(TM) (paliperidone) extended-release tablets is indicated for the acute and maintenance treatment of schizophrenia.
Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA (paliperidone) is not approved for the treatment of patients with dementia-related psychosis.
The most common side effects that occurred with INVEGA were restlessness and extrapyramidal disorder (for example: involuntary movements, tremors and muscle stiffness). One risk of INVEGA is that it may change your heart rhythm. This effect is potentially serious, and you should talk to your doctor about any current or past heart problems. Some medications interact with INVEGA. Please inform your healthcare professional of any medications or supplements that you are taking.
Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal
side effect reported with INVEGA and similar medicines. Call your doctor
immediately if the person being treated develops symptoms such as hi
Copyright©2007 PR Newswire.
All rights reserved